497,186 Shares of TriSalus Life Sciences, Inc. $TLSI Bought by White Pine Capital LLC

White Pine Capital LLC acquired a new position in TriSalus Life Sciences, Inc. (NASDAQ:TLSI – Free Report) in the third quarter, HoldingsChannel reports. The fund acquired 497,186 shares of the company’s stock, valued at approximately $2,143,000.

A number of other hedge funds also recently added to or reduced their stakes in TLSI. Cura Wealth Advisors LLC bought a new position in TriSalus Life Sciences during the 2nd quarter worth about $36,000. Russell Investments Group Ltd. purchased a new position in TriSalus Life Sciences during the 3rd quarter valued at about $68,000. Provenance Wealth Advisors LLC purchased a new position in TriSalus Life Sciences during the 3rd quarter valued at about $94,000. Renaissance Technologies LLC bought a new stake in shares of TriSalus Life Sciences in the 1st quarter valued at about $124,000. Finally, Deutsche Bank AG bought a new stake in shares of TriSalus Life Sciences in the 2nd quarter valued at about $221,000. 2.58% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Zacks Research raised shares of TriSalus Life Sciences to a “hold” rating in a research report on Thursday, September 10th. Citigroup reissued a “buy” rating on shares of TriSalus Life Sciences in a report on Tuesday, November 10th. Wall Street Zen lowered shares of TriSalus Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, November 7th. HC Wainwright reduced their price objective on shares of TriSalus Life Sciences from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 11th. Finally, Stifel Nicolaus set a $12.00 target price on TriSalus Life Sciences in a report on Wednesday, September 23rd. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.20.

View Our Latest Stock Report on TriSalus Life Sciences

TriSalus Life Sciences Price Performance

Shares of TLSI stock opened at $2.43 on Monday. TriSalus Life Sciences, Inc. has a 1-year low of $2.20 and a 1-year high of $7.95. The stock’s 50-day moving average is $4.05 and its 200 day moving average is $4.29. The company has a market cap of $149.64 million, a P/E ratio of -4.96 and a beta of 0.50. The company has a debt-to-equity ratio of 47.60, a current ratio of 4.22 and a quick ratio of 3.86.

TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The business had revenue of $12.88 million during the quarter, compared to the consensus estimate of $14.02 million. Research analysts predict that TriSalus Life Sciences, Inc. will post -0.62 earnings per share for the current fiscal year.

About TriSalus Life Sciences

(Free Report)

TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company’s TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.

Featured Articles

Want to see what other hedge funds are holding TLSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TriSalus Life Sciences, Inc. (NASDAQ:TLSI – Free Report).

Institutional Ownership by Quarter for TriSalus Life Sciences (NASDAQ:TLSI)

Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.